Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
Publication Date: November 29, 2018
Key Points
Key Points
Women with node-positive breast cancer should receive extended therapy including an aromatase inhibitor (AI) for up to a total of 10 years of adjuvant endocrine treatment.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Treatment
...Treatment...
...Updat...
...women with node-negative breast cancer are p...
...ith node-positive breast cancer should be off...
...ing extended adjuvant endocrine therapy sh...
...secondary or contralateral breast c...
...rapy carries ongoing risks and side effects, whi...
...Recomme...
...mends that higher risk patients should r...
...men with Stage II or Stage III breast cancers w...
...I or II breast cancers at higher r...
...Stage I breast cancers not warranting chemo...
...-negative cancers 1 centimeter or less (T1a, T1...
...pression may be administered with either tamoxi...
Table 1. Recommended Pharmaceuticals for HR+ Br...
Table 2. Prognostic Factors for Recurrence A...